Injection-site haematoma

The longitudinal, postmarketing, observational PATRO children study (N = 1837, mean age = 9.33 years, 56.9% male) found that adverse events associated with Omnitrope with an incidence rate >0.001 (based on 2851.16 patient years) were headache, hypothyroidism, arthralgia, pain in extremity, injection-site haematoma, decreased glucose tolerance, asthenia, injection-site pain, increased blood creatine, phosphokinase and myalgia [36 -]. There were no confirmed cases of diabetes (type 1 or 2) or malignancy related to treatment and no anti-hGH antibodies have been found in a subset of 30 patients. 

After 3 months, nerve conduction studies and ultrasonography were repeated and the clinical outcome determined. Eight patients with nine UNEs were included. None of the patients mentioned increase in the symptoms directly after the injection nor did any have any infection on the injection site or haematoma. After 3 months there was improvement of fhe symptoms in five patients. One patient deteriorated and three had no change of the symptoms at all. Overall, there was no significant change of the thickness of the ulnar nerve with mean difference -0.056 mm. It, therefore, becomes obvious that injection with corticosteroids in patients with UNE is easy and safe, and based on this result, enough arguments were found to launch a prospective, placebo-controlled trial to explore the effectiveness of corticosteroids in patients witii UNE. 

Drug administration Over the 2-year trial, 4 of 564 individuals on liraglutide 2.4 mg discontinued use because of injection-site reactions (e.g. pain/extravasation, haematoma, irritation and discomfort). [47 ]... 

---